id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-260923-hwvtxy9g	Jain, Amit	Dexmedetomidine: another arrow in the quiver to fight COVID-19 disease in intensive care units	2020-10-14		.txt	text/plain	619	45	30	While dexmedetomidine-mediated improvements in hypoxic pulmonary vasoconstriction and ventilation-perfusion ratios were proposed explanations for improved oxygenation following dexmedetomidine administration in COVID-19 patients, 12 dexmedetomidine's anti-inflammatory properties may also be instrumental in reducing disease severity. 7 There are several putative mechanisms by which dexmedetomidine might be advantageous in COVID-19 patients Hypoxia inducible factor-1α (HIF-1α) induced changes in monocyte metabolism by SARS-CoV-2 infection has been identified to inhibit T-cell response directly and reduce epithelial cell survival. Effect of sedation with dexmedetomidine versus lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial Effect of dexmedetomidine on mortality and ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical trial Dexmedetomidine improved renal function in patients with severe sepsis: an exploratory analysis of a randomized controlled trial	./cache/cord-260923-hwvtxy9g.txt	./txt/cord-260923-hwvtxy9g.txt